Market Place
Sourcing Support
Novartis` Atectura Breezhaler Receives Approval in Europe
08 Dec 2022 //
EMA
Glenmark launches FDC asthma medication in India
15 Jun 2022 //
ET HEALTH
Novartis Europharm Generic Bemrist (Indacaterol)Receives Approval in Europe
24 Jun 2020 //
EMA
Novartis’ asthma triple heads CHMP’s latest meeting
05 May 2020 //
PMLIVE
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been for Approval
01 May 2020 //
PRNEWSWIRE
First triple combination therapy for asthma with optional electronic sensor
30 Apr 2020 //
EMA
With EMA review in progress, Novartis unveils more data on asthma therapy
06 Dec 2019 //
END PTS
Sosei Heptares Announces Ultibro Breezhaler Included in Drug Reimbursement List
28 Nov 2019 //
PR NEWSWIRE
Novartis hits targets in late-stage QMF149 asthma trial
01 Jun 2019 //
PHARMATIMES
Novartis rolls out heart-helping data for Ultibro COPD edge
24 Feb 2018 //
FIERCE PHARMA
Novartis’ Ultibro Breezhaler reduces lung hyperinflation in COPD patients
23 Feb 2018 //
PHARMA TIMES
Five firms named in breaches of ABPI code
15 Sep 2017 //
PHARMA TIMES
Delhi HC Quashes Cipla`s appeal, says it can`t market generics, Novartis` Onbrez
10 Mar 2017 //
ECONOMIC TIMES
Novartis Out-Licenses Three COPD Products in the US
22 Dec 2016 //
PR NEWSWIRE
Lupin to market Novartis` inhaler under Loftair brand name
11 Apr 2016 //
ECONOMIC TIMES
Big Pharma`s bet on Big Data creates opportunities and risks
26 Jan 2016 //
REUTERS
Onbrez case: Delhi High Court reserves decision on Novartis-Cipla patent dispute
15 Sep 2015 //
THE ECONOMIC TIMES
Novartis COPD therapies hit Phase III targets
21 May 2015 //
PHARMA TIMES
HC Reserves Order on Novartis-Cipla Drug Dispute
17 Dec 2014 //
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.